TipRanks
A new year, a new addition to the stock portfolio what can make more sense than that? The right time to buy, of course, is when stocks are priced at the bottom. Buying low and selling high may be a bit hackneyed, but its true, and truth has staying power.But the markets are up. The NASDAQ rose 43% in 2020, and the S&P 500 showed a gain of 16%. With a market environment like that, finding stocks that are caught in the doldrums is harder than it looks. That's where the Wall Street pros can lend a hand.We used TipRanks' database to pinpoint three stocks that fit a profile: a share price that has dropped over 30% in the last 12 months, but with at least double-digit upside potential, according to analysts. Not to mention each has earned a Moderate or Strong Buy consensus rating.Esperion (ESPR)We will start with Esperion, a company that specializes in therapies for the treatment of elevated low-density lipoprotein cholesterol levels a major factor contributing to heart disease. The companys main product, bempedoic acid, is now available in tablet form under the brand names Nexletol and Nexlizet.In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14,000 patients with top-line data expected in the second half of 2022. The study covers 1,400 locations in 32 countries around the world.Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. Along with the drop in share value, the company showed a fall in revenue from Q2 to Q3, with the top line collapsing from $212 million to $3.8 million. Since the Q3 report, Esperion announced pricing on a $250 million offer of senior subordinated notes, at 4%, due in 2025. The offering gives the company a boost in available capital for further work on its development pipeline and its marketing efforts for bempedoic acid.Chad Messer, covering ESPR for Needham, sees the note offering as a net positive for Esperion. We believe this cash position will be sufficient to support Esperion through 2021 and to profitability in 2022... We believe this financing should help put to rest concerns regarding Esperion's balance sheet. Despite a challenging launch for NEXLETOL and NEXLIZET, product growth has continued in 3Q against the backdrop of a contracting LDL-C market. This growth trajectory suggests potential for a rapid acceleration when conditions improve," Messer wrote.To this end, Messer rates ESPR shares a Strong Buy, and his price target, at $158, suggests the stock has room for huge growth this year up to 481% from current levels. (To watch Messers track record, click here)Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target of $63.33, implying a one-year upside of 133%. (See ESPR stock analysis on TipRanks)Intercept Pharma (ICPT)Liver disease is a serious health threat, and Intercept Pharma is focused on developing treatments for some of the more dangerous chronic liver conditions, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Intercept has a research pipeline based on FXR, a regulator of bile acid pathways in the hepatic system.FXRs action affects not just the bile acid metabolism, but also the glucose and lipid metabolisms, and inflammation and fibrosis around the liver. The lead compound, obeticholic acid (OCA), is an analog of the bile acid CDCA, and as such can take a role in the FXR pathways and receptors implicated in chronic liver disease. Treating liver disease through the FXR biology has direct applications for PBC, and is showing promise treating complications from NASH.ICPT shares dropped sharply last summer, when the FDA rejected the companys application to approve OCA for treatment of NASH-related liver fibrosis. This delays the drugs potential entry to a lucrative market; there is no current treatment for NASH, and the first drug to win approval will have the lead in reaching a market estimated at $2 billion to $5 billion in potential annual sales. The effect on the stock is still felt, and ICPT remains at its 52-week low point.In reaction, in December of 2020, Intercept announced major changes in top-level management, as CEO and President Mark Pruzanski announced he's stepping down effective January 1 of this year. He is succeeded by Jerome Durso, formerly the companys COO, who will also take a post on the Board of Directors. Pruzanski will remain as an advisor, and will hold a directors position on the companys Board.Piper Sandler analyst Yasmeen Rahimi takes a deep dive into Intercepts continuing efforts to expand applications of OCA and to resubmits its New Drug Application to the FDA. She sees the leadership transition as part of these efforts, and writes, [We] believe that Dr. Pruzanski's dedication to transform the liver space is still strong, and that he will continue to guide ICPT's progress as an advisor and Board member. Additionally, we have had the pleasure of working closely with Jerry Durso and believe that he will transform the company and lead ICPT's success in growing the PBC market and the path to potential approval and commercial launch of OCA in NASH.Rahimi takes a long-term bullish stance on ICPT, giving the stock an Overweight (i.e. Buy) rating and an $82 price target. This figure indicates an impressive 220% upside for the next 12 months. (To watch Rahimis track record, click here)Wall Street is somewhat more divided on the drug maker. ICPT's Moderate Buy consensus rating is based on 17 reviews, including 8 Buys and 9 Holds. Shares are priced at $25.82, and the average price target of $59.19 suggests an upside potential of 132% for the next 12 months. (See ICPT stock analysis on TipRanks)Gilead Sciences (GILD)Gilead has had a year like a firework fast up and fast down. The gains came in 1H20, when it appeared that the companys antiviral drug remdesivir would become a prime treatment for COVID-19. By November, however, even though remdesivir had been approved, the World Health Organization (WHO) was recommending against its use, and the COVID vaccines now on the market have made remdesivir irrelevant to the pandemic.This was only one of Gileads recent headwinds. The company has been working, in conjunction with Galapagos (GLPG), on development of filgotinib as a treatment for rheumatoid arthritis. While the drug received EU and Japanese approval in September 2020, the FDA has withheld approval and Gilead announced in December that it was suspending US development efforts on the drug.Even so, Gilead retains a diverse and active research pipeline, with over 70 research candidates at varying stages of the development and approval process for a wide range of diseases and conditions, including HIV/AIDS, inflammatory & respiratory diseases, cardiovascular disease, and hematology/oncology.On a positive note, Gilead posted Q3 earnings above estimates, with the top line revenue, of $6.58 billion, beating the forecast by 6% and growing 17% year-over-year. The company updated its full-year 2020 guidance on product sales from $23 billion to $23.5 billion.Among the bulls is Oppenheimer analyst Hartaj Singh, who gives GILD shares an Outperform (i.e. Buy) rating and $100 price target. Investors stand to pocket a 69% gain should the analysts thesis play out. (To watch Singhs track record, click here)Backing his stance, Singh writes, We continue to believe in our thesis of (1) a dependable remdesivir/other medicines business against SARS-CoV flares, (2) a base business (HIV/oncology/HCV) growing low-single digits over the next couple of years, (3) operating leverage providing greater earnings growth, and (4) a 3-4% dividend yield. What does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 10 Buys, 12 Holds and 1 Sell add up to a Moderate Buy consensus. In addition, the $73.94 average price target indicates 25% upside potential from current levels. (See GILD stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- FTC Settlement With Fertility-Tracking App May Have Costly Ramifications for Companies Who Use Third-Party Data Analytics Software - JD Supra - February 20th, 2021
- Would Americans Have More Babies if the Government Paid Them? - Yahoo News - February 20th, 2021
- Stem cells can give new life to ovaries and potentially restore fertility - Massive Science - February 17th, 2021
- Fertility Among Immigrants and Native-Born Americans - Immigration Blog - February 17th, 2021
- Boost your fertility with oysters, seaweed and other foods - Lowvelder - February 17th, 2021
- Shropshire professor appointed to world-leading fertility organisation - shropshirestar.com - February 17th, 2021
- Rape trial hears Indigenous tour guide offered to help alleged victims with fertility, trauma - ABC News - February 17th, 2021
- Do you really need IVF? This free online tool can help you weigh up your options - News24 - February 17th, 2021
- How A Once-In-A-Lifetime Pandemic Created Fertile Ground For Workplace And Organizational Transformation - Forbes - February 16th, 2021
- Fertility play Virtus Health continues its strong form with profits doubling - Stockhead - February 16th, 2021
- Trumps Popularity Among Republicans Is on the Rise - New York Magazine - February 16th, 2021
- The fertility hormone test you can take at home | Modern ... - February 14th, 2021
- Men's Clinic in Johannesburg | Men's Clinic, Penis ... - February 14th, 2021
- The best 10 Gynaecology & Obstetrics in Johannesburg 2021 - February 14th, 2021
- Governor Cuomo Announces New Actions to Expand Access to Fertility Coverage for Same Sex Couples as Part of 2021 Women's Agenda - ny.gov - February 14th, 2021
- Utah bill would help Medicaid patients diagnosed with cancer preserve ability to have children - Salt Lake Tribune - February 14th, 2021
- Column: Everyone has to pay when America gets too old - Yakima Herald-Republic - February 14th, 2021
- Tips to Boost Fertility in Women With PCOS/PCOD - India.com - February 14th, 2021
- Sexual and Reproductive Health Awareness Day: Protect your fertility by preventing STIs - Times Now - February 14th, 2021
- Surprising things that affect female fertility | Features | wfmz.com - 69News WFMZ-TV - February 14th, 2021
- 'Practicing Catholic' show focuses on practicing fertility awareness - TheCatholicSpirit.com : TheCatholicSpirit.com - The Catholic Spirit - February 14th, 2021
- Conspiracy theories of QAnon find fertile ground in an unexpected place the yoga world - Minneapolis Star Tribune - February 14th, 2021
- How Food Choices Affect Fertility & What You Should Actually Be Eating - BabyGaga - February 14th, 2021
- Thailand sees alarming drop in total fertility rate - The Star Online - February 14th, 2021
- Fertility drugs for women Market 2021-2028 Is Booming Worldwide with Comprehensive Study Explores Huge Revenue Scope in Future KSU | The Sentinel... - February 14th, 2021
- Global Fertility Enhancing Treatment Market 2020 Industry Analysis Report, Regional Outlook, Application Development Potential, Competitive Share... - February 14th, 2021
- Health Department Reports Record Low Fertility Rate in Thailand - Chiang Rai Times - February 14th, 2021
- The Femtech Market Is Booming. Here Are Some of the Risks and Rewards - The Story Exchange - January 31st, 2021
- Donor Egg IVF Services Market Research Report by Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire - January 31st, 2021
- Fertile Ground May Be Virtual This Year, but It's Still Vibrant - Willamette Week - January 31st, 2021
- Legal marijuana: why it could be fertile ground for the next mega-brand - The Drum - January 31st, 2021
- Can the COVID vaccine affect fertility? The short answer is no - KTVI Fox 2 St. Louis - January 20th, 2021
- Philips and Merck partner to develop personalised fertility treatment - Mobihealth News - January 20th, 2021
- Ovation Fertility Fort Worth Announced as Ovation's Newest Lab Location - GlobeNewswire - January 20th, 2021
- RMA of Connecticut Creates Initiative to Educate Prospective Fertility Patients on the Importance of Using SART Data to Choose the Best Fertility... - January 20th, 2021
- The future of fertility | WIRED UK - Wired.co.uk - January 20th, 2021
- Some women are scared about the Covid vaccine harming their fertility should they be? - Telegraph.co.uk - January 20th, 2021
- Global Fertility Test Market Analysis of Key Players, End User, Demand and Consumption By 2026 - KSU | The Sentinel Newspaper - January 20th, 2021
- In-Vitro Fertilization Services Market To Witness Relatively Significant Growth During Forecast to 2026 - KSU | The Sentinel Newspaper - January 20th, 2021
- Korea's KAHF-Designated Hospitals Taking the Lead in Protecting Rights and Interest of International Patients and Offering Quality Medical Services -... - January 20th, 2021
- Disparities in Fertility Treatments, Another Layer of Racism - BELatina - January 20th, 2021
- We're Watching These Trends At Jinxin Fertility Group (HKG:1951) - Simply Wall St - January 20th, 2021
- Revealed: the dairy secret of high fertility and high yield - Wales Farmer - January 20th, 2021
- FTC Reaches Settlement With Flo Health Over Fertility-Tracking App - The Wall Street Journal - January 15th, 2021
- Developer of Popular Women's Fertility-Tracking App Settles FTC Allegations that It Misled Consumers About the Disclosure of their Health Data, FTC... - January 15th, 2021
- Fellow receives clinical validation for mail-in, male fertility test in recently published journal article, ushering in a new era for men, clinicians... - January 15th, 2021
- How every state's population compares to countries around the world - Roanoke Times - January 15th, 2021
- Medical expert seeks to debunk myths that Covid-19 vaccines affect fertility - Belfast Telegraph - January 15th, 2021
- Impact of Covid-19 on Fertility Medicines Market Influencing the Industry Development and Forecast |Allergan Plc, Ferring BV, Merck KGaA, Novartis AG,... - January 15th, 2021
- Fertile-Beltrami community rallies around family of mother and daughter killed in Grand Forks downtown crash - INFORUM - January 15th, 2021
- The best prenatal vitamins for women and how to take them to boost your fertility - Insider - INSIDER - January 15th, 2021
- Your guide to a fertility checkup - The Indian Express - January 15th, 2021
- Canadian millions help fast track expansion of Bourn Hall fertility capacity - Business Weekly - January 15th, 2021
- Apollo Fertility expands its presence with a State-of-the-art Centre - PR Newswire India - January 5th, 2021
- Psychological distress and postponed fertility care during the COVID-19 pandemic - DocWire News - January 5th, 2021
- Planning to start a family this year, here are 5 fertility tips - Times of India - January 5th, 2021
- Fertility Treatment and IVF in Czech Republic During the Coronavirus Pandemic - Prague Morning - January 5th, 2021
- Global Soil Fertility Testing Market 2020 by Company, Regions, Type and Application, Forecast to 2025 - Farming Sector - January 5th, 2021
- A second creation storya human created first - Downtown - Church of the Resurrection - January 5th, 2021
- Argentine black and white tegus are nonnative to Florida, but they're here - and not welcome! - positivelyosceola.com - January 4th, 2021
- The Impact of COVID-19 on the Fertility Sector - BioNews - December 21st, 2020
- No evidence to suggest that COVID-19 impacts fertility: Gynaecologist - United News of India - December 21st, 2020
- Option To Freeze Ovarian Tissue Gives Young Cancer Patients - On the Pulse - December 21st, 2020
- Baby Born from 27-Year-Old Embryo: What This Means for the Future - Healthline - December 21st, 2020
- 16 Natural Ways to Boost Fertility - Healthline - December 20th, 2020
- IRMS Jersey City Office - IRMS Reproductive Medicine - December 20th, 2020
- University of Miami researchers studying effects of COVID-19 vaccine and male fertility - Newswise - December 20th, 2020
- Fantasia Barrino Gets Candid About Fertility Struggle: This Is A Three-Year Journey Weve Been On - ETCanada.com - December 20th, 2020
- Technological Advancement in Fertility Drug Market 2020 with Growth Analysis of Global Market & Forecast to 2026 - LionLowdown - December 20th, 2020
- Jackelyn B. Payne, MPH, MA, on Fertility Preservation in AYAs with Cancer - Cancer Network - December 18th, 2020
- Physicians Weigh in on TikToker's Claim That Mucinex Improves Fertility - Complex - December 18th, 2020
- Australia's first birth control app has been approved by the TGA. Do they work? - ABC News - December 18th, 2020
- Hitting the pause button: More women exploring fertility options amid ongoing pandemic - WZZM13.com - December 18th, 2020
- Why avoiding a nation-wide two-child policy is the right decision - Business Standard - December 18th, 2020
- Progyny CEO on the future of fertility treatments amid COVID-19 - Yahoo Finance - December 18th, 2020
- Covid vaccine and fertility: What you need to know - Metro.co.uk - December 18th, 2020
- EXCLUSIVE: Dr Aswati Nair on the link between obesity and male fertility - PINKVILLA - December 11th, 2020
- Assessing the impacts of global climate change on population trends - Newswise - December 11th, 2020
- Breast Cancer in Childbearing Years: Fertility Preservation Prior to Treatment Improves Outcomes for Survivors - Oncology Nurse Advisor - December 9th, 2020
- Apollo Fertility expands into Kolkata with a state-of-the-art Centre - PR Newswire India - December 9th, 2020